Hagop M. Kantarjian
University of Texas MD Anderson Cancer Center
4152 Papers
32.7K Citations
Hagop M. Kantarjian is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 204, co-authored 3708 publications. Previous affiliations of Hagop M. Kantarjian include Rice University & University of Chicago.
Chat about Author
Papers
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104
Juliana Benito,Yuexi Shi,Barbara Szymanska,Hernan Carol,Ingrid Boehm,Hongbo Lu,Sergej Konoplev,Wendy Fang,Patrick A. Zweidler-McKay,Dario Campana,Gautam Borthakur,Carlos E. Bueso-Ramos,Elizabeth J. Shpall,Deborah A. Thomas,Craig T. Jordan,Hagop M. Kantarjian,William R. Wilson,Richard B. Lock,Michael Andreeff,Marina Konopleva +19 more
TL;DR: It is demonstrated that administration of the hypoxia-activated dinitrobenzamide mustard, PR-104 prolonged survival and decreased leukemia burden of immune-deficient mice injected with primary acute lymphoblastic leukemia cells is demonstrated to be feasible and may significantly improve leukemia therapy.
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Elihu H. Estey,Francis J. Giles,Hagop M. Kantarjian,Susan O'Brien,Jorge E. Cortes,Emil J. Freireich,Gabriel Lopez-Berestein,Michael J. Keating +7 more
TL;DR: The data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed acute promyelocytic leukemia (APL), and similar to that observed in a previous study using oral ATRA + idarubicin.
126
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
Miloslav Beran,Hagop M. Kantarjian,Susan O'Brien,Charles Koller,Maher Albitar,Susan Arbuck,Sherry Pierce,Michael W. Moore,James L. Abbruzzese,Michael Andreeff,Michael J. Keating,Elihu H. Estey +11 more
TL;DR: Topotecan has significant activity in MDS and CMML, with acceptable side effects, and there was evidence of association with a higher response rate for patients with lack of prior chemotherapy, less than 10% marrow monocytes, and absence of RAS oncogene mutations.
126
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
Daniel J. DeAngelo,Wendy Stock,Anthony S. Stein,Andrei R. Shustov,Michaela Liedtke,Charles A. Schiffer,Erik Vandendries,K. F. Liau,Revathi Ananthakrishnan,Joseph Boni,A. Douglas Laird,Luke Fostvedt,Hagop M. Kantarjian,Anjali S. Advani +13 more
TL;DR: InO was well tolerated and demonstrated high single-agent activity and MRD-negativity rates and achievement of MRD negativity was associated with higher InO exposure.
126
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Courtney Dinardo,Andre C. Schuh,Eytan M. Stein,Pau Montesinos,Andrew H. Wei,Stéphane de Botton,Amer M. Zeidan,Amir T. Fathi,Hagop M. Kantarjian,John M. Bennett,Mark G. Frattini,Patricia Martin-Regueira,Frederik Lersch,Jing Gong,Maroof Hasan,Paresh Vyas,Hartmut Döhner +16 more
TL;DR: In this article, the safety and activity of enasidenib plus azacitidine versus azacetidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia ineligible for intensive chemotherapy was evaluated.
125